Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Alessandra Siegmann"'
Autor:
Sophia Scharl, Luca Gartner, Dirk Heinz Gerhard Boehmer, Alessandra Siegmann, Daniel Zips, Reinhard Thamm, Thomas Wiegel
Publikováno v:
Journal of Clinical Oncology. 41:367-367
367 Background: Salvage radiotherapy (SRT) alone or in combination with androgen deprivation therapy (ADT) is the only curative treatment option for patients with biochemical recurrence after radical prostatectomy (RP) for prostate cancer. An undetec
Autor:
Derya Tilki, Felix Preisser, Reinhard Thamm, Raisa S. Pompe, Felix K.-H. Chun, Markus Graefen, Alessandra Siegmann, Dirk Böhmer, Volker Budach, Thomas Wiegel
Publikováno v:
Cancers, Vol 14, Iss 740, p 740 (2022)
Cancers; Volume 14; Issue 3; Pages: 740
Cancers
Cancers; Volume 14; Issue 3; Pages: 740
Cancers
Salvage radiotherapy improves oncologic outcomes in prostate cancer patients who develop biochemical recurrence after radical prostatectomy. However, the evidence on hard clinical endpoints is scarce. Within this study, we compare the long-term oncol
Publikováno v:
BJU International. 124:785-791
OBJECTIVE To test whether salvage radiotherapy (SRT) in patients with lymph node negative (N0) prostate cancer is equally effective with persistent prostate-specific antigen (PSA) and PSA rising from the undetectable range (
Autor:
Dirk Böhmer, Thomas Wiegel, Volker Budach, Reinhard Thamm, Dirk Bottke, Alessandra Siegmann, Detlef Bartkowiak
Publikováno v:
Prostate Cancer and Prostatic Diseases. 22:344-349
For patients with recurrent prostate cancer after radical prostatectomy (RP), salvage radiotherapy (SRT) offers a second chance of cure. European guidelines (EAU) recommend SRT at a PSA
Autor:
Dirk Böhmer, Alessandra Siegmann, Sophia Scharl, Christian Ruf, Thomas Wiegel, Manuel Krafcsik, Reinhard Thamm
Publikováno v:
Cancers; Volume 14; Issue 5; Pages: 1320
Previous randomized trials have not provided conclusive evidence about dose escalations and associated toxicities for salvage radiotherapy (SRT) in prostate cancer. Here, we retrospectively analyzed whether dose escalations influenced progression-fre
Autor:
Hartwig Huland, Thomas Wiegel, Alessandra Siegmann, Georg Salomon, Dirk Boehmer, Christoph Wuernschimmel, Philipp Gild, Sami-Ramzi Leyh-Bannurah, Volker Budach, Raisa S. Pompe, Margit Fisch, Derya Tilki, Detlef Bartkowiak, Felix Preisser, Markus Graefen
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:Recently, a new risk stratification of patients harboring biochemical recurrence (BCR) after radical prostatectomy (RP) has been proposed by the EAU: EAU low-risk BCR (Gl...
Autor:
Felix K.-H. Chun, Raisa S. Pompe, Felix Preisser, Derya Tilki, Markus Graefen, Dirk Böhmer, Alessandra Siegmann, Hartwig Huland, Thomas Wiegel, Detlef Bartowiak, Volker Budach
Publikováno v:
Journal of Urology. 203
INTRODUCTION AND OBJECTIVE:Salvage radiotherapy (SRT) may lead to better oncologic outcomes in prostate cancer (PCa) patients who develop biochemical recurrence (BCR) after radical prostatectomy (R...
Autor:
Volker Budach, Reinhard Thamm, Thomas Wiegel, Dirk Böhmer, Detlef Bartkowiak, Alessandra Siegmann
Publikováno v:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 154
In prostate cancer (PCa) recurring after radical prostatectomy (RP), salvage radiotherapy (SRT) is recommended to be given at PSA0.5 ng/ml. It has been speculated, that the advantage from early SRT is mainly caused by lead-time bias: Calculating from
Autor:
Dirk Böhmer, Volker Budach, Detlef Bartkowiak, Raisa S. Pompe, Alessandra Siegmann, Derya Tilki, Reinhard Thamm, Markus Graefen, Thomas Wiegel, H. Huland, F.K.H. Chun, Felix Preisser
Publikováno v:
Radiotherapy and Oncology. 152:S372-S373
Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy
Autor:
Hartwig Huland, Jonas Schiffmann, Detlef Bartkowiak, Thomas Wiegel, Pierre Tennstedt, Volker Budach, Dirk Böhmer, Markus Graefen, Lars Budäus, Alessandra Siegmann
Publikováno v:
Strahlentherapie und Onkologie. 193:692-699
The optimal prostate-specific antigen (PSA) level after radical prostatectomy (RP) for defining biochemical recurrence and initiating salvage radiation therapy (SRT) is still debatable. Whereas adjuvant or extremely early SRT irrespective of PSA prog